Free Trial
OTCMKTS:CLPBY

Coloplast A/S (CLPBY) Stock Price, News & Analysis

$13.69
+0.36 (+2.70%)
(As of 09/6/2024 ET)
Today's Range
$13.57
$13.75
50-Day Range
$12.06
$14.03
52-Week Range
$9.90
$14.34
Volume
37,335 shs
Average Volume
148,040 shs
Market Capitalization
$29.57 billion
P/E Ratio
41.49
Dividend Yield
0.66%
Price Target
N/A
CLPBY stock logo

About Coloplast A/S Stock (OTCMKTS:CLPBY)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

CLPBY Stock Price History

CLPBY Stock News Headlines

Ex-CIA Advisor: “This is How Kamala will Rig the Election”
A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…
Ex-CIA Advisor: “This is How Kamala will Rig the Election”
A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…
Coloplast A/S (CLPBY)
Coloplast A/S - Allocation of Share Options
Coloplast A/S - Allocation of Share Options
Coloplast A/S - Interim Financial Report, Q1 2023/24
Coloplast A/S ADR
Coloplast A/S goes ex-dividend tomorrow
See More Headlines
Receive CLPBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/20/2024
Today
9/07/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Current Symbol
OTCMKTS:CLPBY
Previous Symbol
NASDAQ:CLPBY
Fax
N/A
Employees
15,913
Year Founded
1954

Profitability

Net Income
$685.88 million
Pretax Margin
24.66%

Debt

Sales & Book Value

Annual Sales
$3.58 billion
Cash Flow
$0.43 per share

Miscellaneous

Outstanding Shares
2,160,000,000
Free Float
N/A
Market Cap
$29.57 billion
Optionable
Not Optionable
Beta
-0.01

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Kristian Villumsen (Age 54)
    President & CEO
    Comp: $2.55M
  • Mr. Anders Lonning-Skovgaard (Age 52)
    Executive VP & CFO
    Comp: $1.31M
  • Mr. Allan Rasmussen (Age 57)
    Executive Vice President of Global Operations
    Comp: $1.15M
  • Mr. Nicolai Buhl Andersen (Age 55)
    Executive Vice President of Innovation
    Comp: $1.11M
  • Mr. Paul Marcun (Age 57)
    Executive Vice President of Growth
    Comp: $1.33M
  • Mr. Thomas Barfod (Age 54)
    Senior Controller & Employees Representative Director
    Comp: $65.68k
  • Ellen Bjurgert
    Vice President of Investor Relations
  • Dennis Kaysen
    Director of Corporate Communications
  • Dorthe Ronnau (Age 58)
    Senior Vice President of People & Culture
  • Mr. Alain Morvan
    Senior Vice President of Sales Europe

Should I Buy Coloplast A/S Stock? CLPBY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Coloplast A/S:

  • Coloplast A/S has shown a consistent decrease in short interest, indicating potential positive market sentiment.
  • The company's stock price has been relatively stable, with a 50-day simple moving average of $12.97 and a 200-day simple moving average of $12.91.
  • Coloplast A/S reported a net margin of 19.45% and a return on equity of 36.74%, showcasing strong financial performance.
  • The company's revenue for the last reported quarter was $993.49 million, demonstrating robust business operations.
  • Equities research analysts expect Coloplast A/S to post earnings per share of 0.34 for the current year, indicating potential growth.

Cons

Investors should be bearish about investing in Coloplast A/S for these reasons:

  • Short interest in Coloplast A/S experienced a significant increase in July, which could signal uncertainty or negative sentiment in the market.
  • The company's price-to-earnings ratio is relatively high at 41.42, which may indicate that the stock is overvalued compared to its earnings.
  • Coloplast A/S has a price-to-earnings-growth ratio of 3.22, suggesting that the stock may be considered expensive relative to its growth prospects.
  • The company's beta of -0.02 indicates low volatility compared to the market, potentially limiting opportunities for high returns.
  • Coloplast A/S has a debt-to-equity ratio of 0.71, which could pose risks related to financial leverage and debt management.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 4, 2024. Please send any questions or comments about these Coloplast A/S pros and cons to contact@marketbeat.com.

CLPBY Stock Analysis - Frequently Asked Questions

How have CLPBY shares performed this year?

Coloplast A/S's stock was trading at $11.53 at the beginning of the year. Since then, CLPBY stock has increased by 18.7% and is now trading at $13.69.
View the best growth stocks for 2024 here
.

How were Coloplast A/S's earnings last quarter?

Coloplast A/S (OTCMKTS:CLPBY) announced its earnings results on Tuesday, August, 20th. The company reported $0.08 earnings per share (EPS) for the quarter. The company earned $993.49 million during the quarter. Coloplast A/S had a net margin of 18.89% and a trailing twelve-month return on equity of 31.54%.

How do I buy shares of Coloplast A/S?

Shares of CLPBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:CLPBY) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners